EW
NKTR icon

Evoke Wealth’s Nektar Therapeutics NKTR Stock Holding History

Evoke Wealth’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-398
Closed -$32K – 1213
2022
Q1 		$32K Sell
398
-135
-25% -$20K ﹤0.01% 582
2021
Q4 		$108K Hold
533
– – ﹤0.01% 433
2021
Q3 		$143K Buy
+533
New +$128K 0.01% 381
2020
Q4 		– Sell
-10
Closed -$2K – 1068
2020
Q3 		$2K Hold
10
– – ﹤0.01% 854
2020
Q2 		$3K Buy
10
+3
+43% +$936 ﹤0.01% 801
2020
Q1 		$1.75K Sell
7
-21
-75% -$6.5K ﹤0.01% 825
2019
Q4 		$9.13K Hold
28
– – ﹤0.01% 776
2019
Q3 		$7.7K Buy
+28
New +$10.3K ﹤0.01% 887

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Evoke Wealth's NKTR Position: Q2 2022 in Review

Evoke Wealth sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 398 shares — an estimated $32K sold.

Evoke Wealth first reported a position in NKTR in Q3 2019 and held it in 8 quarters. The position peaked at $143K in Q3 2021. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

  • Evoke Wealth reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Evoke Wealth sold 398 Nektar Therapeutics shares in Q2 2022, an estimated $32K.
  • Evoke Wealth first reported a position in Nektar Therapeutics in Q3 2019 and held it in 8 quarters.
  • Evoke Wealth's Nektar Therapeutics position peaked at $143K in Q3 2021.
  • 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on Evoke Wealth's 13F filing for Q2 2022, filed 4 Aug 2022.